More Data Backs Tecentriq As IMpower133 Combo Meets Primary SCLC Endpoints

25 Jun 2018

• By Sten Stovall

IMpower133 trial combining Tecentriq with chemotherapy in first-line small cell lung cancer met both its OS and PFS endpoints.

Carcinoma — Roche has 8 Phase III lung cancer studies underway evaluating Tecentriq alone or in combination • Source: Shutterstock

Roche's Phase III IMpower133 trial has met its co-primary endpoints in extensive-stage small cell lung cancer patients, adding to growing evidence backing use of Tecentriq-based combinations to treat different types of advanced lung cancer.

IMpower133's first interim analysis showed that combining Tecentriq (atezolizumab) with chemotherapy helped people with extensive-stage small cell lung cancer live...